207 related articles for article (PubMed ID: 35202550)
41. Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
Li L; Zhou R; Geng H; Yue L; Ye F; Xie Y; Liu J; Kong X; Jiang H; Huang J; Luo C
Bioorg Med Chem Lett; 2014 May; 24(9):2090-3. PubMed ID: 24709560
[TBL] [Abstract][Full Text] [Related]
42. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
[TBL] [Abstract][Full Text] [Related]
43. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
[TBL] [Abstract][Full Text] [Related]
44. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).
Borkin D; Pollock J; Kempinska K; Purohit T; Li X; Wen B; Zhao T; Miao H; Shukla S; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2016 Feb; 59(3):892-913. PubMed ID: 26744767
[TBL] [Abstract][Full Text] [Related]
45. Interaction of MLL amino terminal sequences with menin is required for transformation.
Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
[TBL] [Abstract][Full Text] [Related]
46. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
47. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
48. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
Yokoyama A; Wang Z; Wysocka J; Sanyal M; Aufiero DJ; Kitabayashi I; Herr W; Cleary ML
Mol Cell Biol; 2004 Jul; 24(13):5639-49. PubMed ID: 15199122
[TBL] [Abstract][Full Text] [Related]
49. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
50. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.
Kühn MW; Armstrong SA
Cancer Cell; 2015 Apr; 27(4):431-3. PubMed ID: 25873167
[TBL] [Abstract][Full Text] [Related]
51. Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility.
Senter T; Gogliotti RD; Han C; Locuson CW; Morrison R; Daniels JS; Cierpicki T; Grembecka J; Lindsley CW; Stauffer SR
Bioorg Med Chem Lett; 2015 Jul; 25(13):2720-5. PubMed ID: 25987377
[TBL] [Abstract][Full Text] [Related]
52. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
53. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups.
Lei H; Zhang SQ; Bai H; Zhao HY; Sun J; Chuai H; Xin M
J Med Chem; 2022 Oct; 65(19):13413-13435. PubMed ID: 36173787
[TBL] [Abstract][Full Text] [Related]
54. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.
Bai H; Yang Z; Lei H; Wu Y; Liu J; Yuan B; Ma M; Gao L; Zhang SQ; Xin M
Eur J Med Chem; 2024 Mar; 268():116226. PubMed ID: 38367493
[TBL] [Abstract][Full Text] [Related]
55. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
[TBL] [Abstract][Full Text] [Related]
56. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
Stubbs MC; Krivtsov AV
Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
[TBL] [Abstract][Full Text] [Related]
57. [Interaction between mixed-lineage leukemia and Menin proteins].
Liu L; Li BS; Ye QD; He YY; Tang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1130-4. PubMed ID: 19840436
[TBL] [Abstract][Full Text] [Related]
58. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
59. NUP98-MLL fusion in human acute myeloblastic leukemia.
Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
[TBL] [Abstract][Full Text] [Related]
60. The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells.
Shah CA; Bei L; Wang H; Platanias LC; Eklund EA
J Biol Chem; 2013 Nov; 288(45):32490-32505. PubMed ID: 24089521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]